Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 5-10 years (±3 months)~* permanent residents of the area~* absence of history of hypersensitivity reactions to the drugs~Exclusion Criteria:~* chronic illness~* severe malnutrition (weight-for-age nutritional Z score \[WAZ\] \<60th percentile)~* severe anemia (Hb \<5 g/dL),~* G-6-PD deficiency (\<60% G-6-PD activity)~* permanent disability, which prevents or impedes study participation. Any 1 or more of the criteria is sufficient to exclude study participation.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Primaquine (Type: ACTIVE_COMPARATOR): Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD

Based on this trial design, predict the completion outcome and termination type (if applicable).